All In Biotech

Free tool

FAERS Monitor: Zykadia

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 211225 or its brand name (Zykadia, Ceritinib). Reports on generic versions are filed under their own applications.

Reports

2,384

Serious

1,941

81% of reports

Hospitalization

589

Death reported

553

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • malignant neoplasm progression430
  • diarrhoea427
  • nausea343
  • death281
  • vomiting224
  • metastases to central nervous system172
  • fatigue134
  • non-small cell lung cancer130
  • decreased appetite119
  • disease progression112
  • dyspnoea102
  • abdominal pain100
  • asthenia90
  • non-small cell lung cancer stage iv90
  • drug ineffective85

Reports by year received

View as table
YearReports
20132
201498
2015332
2016371
2017311
2018312
2019182
2020182
2021221
2022183
202391
202453
202529
202617

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,051,775 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
non-small cell lung cancer stage ivSignal902900.52293.7194,193
non-small cell lung cancerSignal130246.1207.730,639
metastases to central nervous systemSignal172119.2103.119,792
malignant neoplasm progressionSignal43037.234.115,120
disease progressionSignal1128.47.0722
diarrhoeaSignal4275.85.41,761
decreased appetiteSignal1194.53.8326
vomitingSignal2244.23.7556
nauseaSignal3433.83.5740
abdominal painSignal1003.83.1205
deathSignal2812.92.6357
astheniaSignal902.11.753
dyspnoea1021.61.322
fatigue1341.51.324
drug ineffective850.60.529

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.